Hereditary Haemorrhagic Telangiectasia Working Group (HHT-WG)

Clinical Trials/Observational Studies

Clinical trials play a critical role in advancing medical knowledge and improving patient outcomes. They help to test new treatments, therapies, and medical devices, and provide valuable insights into the safety and effectiveness of these interventions.

Discover the current studies and clinical trials in which the HHT WG is involved, paving the way for breakthroughs in diagnosing, treating and caring for HHT patients.


The SAIPAN-trial is a multicenter, randomized, open-label, parallel group, superiority trial aimed at evaluating the effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding. The SAIPAN-trial brings together members of the HHT WG from Denmark, France, Italy, and the Netherlands. It is currently ongoing and started since 2021.

VAD044 HHT Study – Vaderis

The VAD044 HHT Study is a randomized, placebo controlled, double blind, multicenter study is to assess safety and efficacy of 2 doses of VAD044 in adult HHT patients. It is sponsored by Vaderis Therapeutics. It will also evaluate the effects of the two doses of VAD044 on HHT symptoms and other physiological indicators, and how the study drug enters, moves through and exits the body (Pharmacokinetics or PK).

Skip to content